The story of GLP-1 drugs have had so many plot twists it would almost sound lazy in a medical fiction novel. First the type-2 diabetes drug helps with obesity (and the host of issues with it like sleep apnea and fatty liver). Fine, that tracks. Obesity ties those treads together. Then some people begin mentioning they stopped smoking and had less alcohol cravings after starting a GLP-1 drug. Huh? A bit later, we hear it might be neuroprotective. Okay, WTF is going on here?
Now, the same class of drugs designed for diabetes control turns out to lower intracranial pressure and might relieve migraines. First Ozempic came to make people thinner, and it’s succeeding. It might also end up stopping us migraineurs from clutching our heads in dark rooms. Somewhere, the endocrinologists are smirking.
From Gut Hormone to Brain Whisperer
GLP-1, or glucagon-like peptide-1, is a short-lived hormone released by intestinal L-cells when we eat. It’s what tells the pancreas to release insulin, slow digestion, and make us feel full. It was supposed to be an unglamorous incretin peptide. But GLP-1 receptors also sit in odd places like the hypothalamus, hippocampus, and, most relevant here, the choroid plexus, the brain’s cerebrospinal-fluid factory.
A few things happen when those receptors are activated:
Inflammatory cytokines like IL-1β and TNF-α go down, while IL-10 (the chill cytokine) goes up.
Microglia, the brain’s sometimes-rabid immune cells, calm down and even release β-endorphins.
The sodium–potassium pump in the choroid plexus slows, which reduces CSF production and lowers intracranial pressure (ICP).
That’s an unintentional recipe for treating a headache disorder, even if the drug label still says “Type 2 diabetes.”
The Migraine Connection
Migraine and idiopathic intracranial hypertension without papilledema (IIHWOP for those who enjoy acronyms) share a suspicious number of traits: they mostly affect women, are more common in obesity, feature elevated CGRP (calcitonin-gene–related peptide), and occasionally improve after a lumbar puncture drains some CSF. It’s as though migraine in some people might be a low-grade pressure problem wrapped in a sensory one.
So when animal studies showed that GLP-1 agonists not only lower ICP but also reduce CGRP and c-Fos (a marker of neuronal activation) in the trigeminocervical complex (the hub for headache pain) neurologists perked up. If you can lower both pressure and neuropeptide noise, you might have something new.
The Systematic Review: Early Smoke, Real Fire
A 2024 systematic review in The Journal of Headache and Pain gathered forty-two studies linking GLP-1 signaling to pain or headache. Across models, the pattern was consistent:
GLP-1 receptor activation decreased inflammation, reduced neuronal hyperexcitability, and, in humans with idiopathic intracranial hypertension, lowered ICP independent of weight loss.
In the most notable RCT, exenatide cut intracranial pressure and trimmed about 7.7 monthly headache days compared with placebo. A case-control study of liraglutide and semaglutide users echoed the finding: patients needed less acetazolamide and had fewer headaches even when their weight barely changed. The effect seems to persist long after any caloric virtue signaling wears off.
The Pilot Trial: Liraglutide vs. Migraine
Enter the 2025 Headache paper by Braca et al., a real-world pilot aimed at migraine itself.
Thirty-one obese adults with chronic or high-frequency migraine who had already failed at least two preventive therapies, including CGRP monoclonal antibodies, were put on liraglutide 1.2 mg daily for twelve weeks.
Here’s what they found:
• Monthly Headache Days dropped from 19.8 to 10.7 (-9.1 days, p < 0.001).
• 48 % had at least a 50 % reduction; a quarter had ≥ 75 %.
• MIDAS disability score halved, from 60 to 29.
• BMI didn’t budge (34.0 → 33.9, p = 0.06).
Translation: people’s heads hurt less even though their bathroom scale stayed the same. The regression line between BMI change and headache reduction was flatter than a celebrity’s Ozempic-ified stomach.
Side effects were standard with nausea and constipation, as well as the general sense of being too aware of your GI tract, but no one quit.
Weight Loss? Not This Time
If weight loss drove the effect, we’d expect a tidy correlation between pounds dropped and headache relief. Instead, BMI explained a statistically comical 0.1 % of the variance.
That leaves us with two plausible routes:
1. Pressure reduction: less CSF → less venous-sinus stretch → less trigeminal activation.
2. Neuropeptide modulation: suppressed CGRP release upstream of where antibodies block it.
Where We Are (and Aren’t) Yet
The caveats are obvious: open-label design, no ICP measurements, small sample, short duration. But as pilots go, it’s promising, especially for a patient group that’s usually stuck rotating through preventive medications like a bad speed-dating event.
Future work will need double-blind RCTs with direct or surrogate ICP measures like venous-sinus flow MRI and inclusion of non-obese migraineurs. Biomarkers like CGRP or IL-6 could finally tell us whether pressure and peptide pathways move in sync.
The Bigger Picture
It’s hard not to admire the absurdity: the more we study “metabolic” drugs, the less metabolic they become. GLP-1 agonists now blur lines between endocrinology, neurology, and psychiatry, with hints of benefit for Alzheimer’s, Parkinson’s, addiction, and now migraine.
If the early results hold, these drugs might represent the first preventive that simultaneously reduces intracranial pressure and dials down trigeminal excitability; a neat trick for a molecule that started life managing insulin secretion in the gut.
Bottom Line
GLP-1 receptor agonists probably do more for the brain than we ever meant them to. The evidence for migraine relief is still thin but biologically plausible, and in medicine that’s usually where revolutions start. If GLP-1s keep this rate of discovery for new uses, they’ll need their own medical journals dedicated to them.
The Edge of Epidemiology is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
